The Aviva share price is up 20% in 2021. Should I buy some more?

After a painful crash in 2020, the Aviva share price has come storming back. Is it a good buy for long-term dividend prospects?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

One English pound placed on a graph to represent an economic down turn

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve so far spent 2021 mostly ignoring the shares I already own, and that includes Aviva (LSE: AV). I’m far more interested in the stocks I don’t own but might want to buy in the coming months. Anyway, what’s been happening to the Aviva share price? Well, it looks like it’s up 23% since the start of the year. And yes, I really have only just had a look. Am I neglectful, taking my eye off my share prices? If I’m not thinking of buying or selling Aviva, why should I care?

Since mid-February 2020, before the Covid catastrophe hit, Aviva shares are down 5%. But Aviva has declared a dividend of 21p per share for 2020. Based on the Aviva share price at the start of last year, that’s a 5% yield, wiping out share price drop. I’d say its shareholders had a pretty good year.

Looking back also reinforces for me the danger of selling out when a stock is severely hammered. Aviva collapsed a fair bit harder than the FTSE 100 in general. Those selling during the depths of the crisis suffered a loss of up to 45% at one point — a loss they would have already recovered had they held.

Aviva share price future

But I can understand the sentiment. I mean, pandemic, economic collapse, stock market crash… the whole financial sector was sure to be plunged into ruin, yes? Well, actually, no. Banking shares are still down, but the banks are coming back. Even hard-pressed Lloyds Banking Group has just released upbeat figures for the first quarter of 2021. And insurance?

Judging by Aviva’s 2020 results, released in March, it’s hard to find much impact from the crisis. Operating profit fell by less than 1% from 2019. And profit stated in IFRS terms was actually up. There was no immediate positive sentiment towards the Aviva share price as a result. But then, Aviva has been battling structural problems, which take longer to sort out. 

So what about the outlook for its transformation efforts? After the sale of Aviva France, the company revealed plans to dispose of Aviva Italy in 2021. On completion, it expects to see its excess capital boosted by around £3bn. All the usual liquidity ratios look fine, and progress on debt reduction was strong in 2020.

Long-term problems sorted?

I might sound like I’m painting a glowing picture of the firm here. But I definitely don’t want to downplay the negatives. The Aviva share price is still down 11% over the past 10 years. That’s when the Footsie as a whole gained 15%. The main reason seems to be an institutional view that Aviva had become something of a bloated and slow-moving monster. Some were even calling for a break-up of the company as a way to enhance shareholder value.

And I have to remind myself that, even if I’m looking through optimistic eyes, I’m still sitting on a share price loss since I bought. I do have some decent years of dividends to compensate, mind. The bottom line for me? On 2020 earnings, the current Aviva share price represents a trailing P/E of less than six. I still rate it a buy for me.

Alan Oscroft owns shares of Aviva and Lloyds Banking Group. The Motley Fool UK has recommended Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 top-notch growth shares I want in my Stocks and Shares ISA in 2026

What do a world-famous tech giant and a fast-growing rocket maker have in common? This writer wants them both in…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

How can we get started building a passive income ISA in 2026?

Didn't an ancient Chinese investor say the journey to a passive income fortune begins with a single step? If they…

Read more »

Investing Articles

Seeking New Year bargains? FTSE 100 index shares remain on sale!

These FTSE 100 index stocks have surged in value in 2026. But they still offer plenty for value investors to…

Read more »

Landlady greets regular at real ale pub
Investing Articles

Will the crashed Diageo share price rebound 63% in 2026?

Diageo's share price has collapsed by more than a third since 1 January. But these brokers expect the FTSE 100…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

1 top investment trust to consider from the FTSE 250 

This niche FTSE 250 investment trust offers exposure to one of Asia's fastest growing economies, potentially setting it up for…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

2 high risk/high reward stock market picks to consider in 2026

The coming year could bring about lots of stock market opportunities for brave investors willing to stomach risk. Mark Hartley…

Read more »

Investing Articles

ChatGPT thinks these are the 5 best FTSE stocks to consider buying for 2026!

Can the AI bot come up trumps when asked to select the best FTSE stocks to buy as we enter…

Read more »

Investing For Beginners

How much do you need in an ISA to make the average UK salary in passive income?

Jon Smith runs through how an ISA can help to yield substantial income for a patient long-term investor, and includes…

Read more »